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Summary
Background The outcome of diﬀ use large B-cell lymphoma has been substantially improved by the addition of the 
anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. We aimed to assess, in patients aged 
18–59 years, the potential survival beneﬁ t provided by a dose-intensive immunochemotherapy regimen plus rituximab 
compared with standard treatment plus rituximab.
Methods We did an open-label randomised trial comparing dose-intensive rituximab, doxorubicin, cyclo phosphamide, 
vindesine, bleomycin, and prednisone (R-ACVBP) with subsequent consolidation versus standard rituximab, 
doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). Random assignment was done with a 
computer-assisted randomisation-allocation sequence with a block size of four. Patients were aged 18–59 years with 
untreated diﬀ use large B-cell lymphoma and an age-adjusted international prognostic index equal to 1. Our primary 
endpoint was event-free survival. Our analyses of eﬃ  cacy and safety were of the intention-to-treat population. This 
study is registered with ClinicalTrials.gov, number NCT00140595.
Findings One patient withdrew consent before treatment and 54 did not complete treatment. After a median follow-up of 
44 months, our 3-year estimate of event-free survival was 81% (95% CI 75–86) in the R-ACVBP group and 67% (59–73) 
in the R-CHOP group (hazard ratio [HR] 0·56, 95% CI 0·38–0·83; p=0·0035). 3-year estimates of progression-free 
survival (87% [95% CI, 81–91] vs 73% [66–79]; HR 0·48 [0·30–0·76]; p=0·0015) and overall survival (92% [87–95] vs 84% 
[77–89]; HR 0·44 [0·28–0·81]; p=0·0071) were also increased in the R-ACVBP group. 82 (42%) of 196 patients in the 
R-ACVBP group experienced a serious adverse event compared with 28 (15%) of 183 in the R-CHOP group. Grade 3–4 
haematological toxic eﬀ ects were more common in the R-ACVBP group, with a higher proportion of patients experiencing 
a febrile neutropenic episode (38% [75 of 196] vs 9% [16 of 183]).
Interpretation Compared with standard R-CHOP, inten siﬁ ed immunochemotherapy with R-ACVBP signiﬁ cantly 
improves survival of patients aged 18–59 years with diﬀ use large B-cell lymphoma with low-intermediate risk 
according to the International Prognostic Index. Haematological toxic eﬀ ects of the intensive regimen were raised 
but manageable.
Funding Groupe d’Etudes des Lymphomes de l’Adulte and Amgen.
Introduction
Diﬀ use large B-cell lymphoma is the most common 
haemopoietic malignancy, accounting for 25% of all 
lymphoid neoplasms.1 The clinical course of diﬀ use large 
B-cell lymphoma has greatly changed over the past 
10 years, since the introduction of the chimeric mono-
clonal anti-CD20 antibody rituximab for the treat ment of 
patients with lymphoma. A pivotal trial done in 1998 by 
the Groupe d’Etude des Lymphomes de l’Adulte (GELA) 
showed that combining rituximab with standard cyclo-
phospha mide, doxorubicin, vincristine, and predni sone 
(CHOP) chemo therapy signiﬁ cantly improved response, 
event-free survival, and overall survival compared with 
CHOP alone in patients older than 60 years.2,3 These 
favourable results have been conﬁ rmed by three additional 
randomised trials in patients both younger and older 
than 60 years with diﬀ use large B-cell lymphoma.4–6 
However, despite these signiﬁ cant improve ments, some 
patients are refractory to initial treatment or can relapse 
after a complete response. In cases where the disease is 
refractory to immuno chemotherapy, the esti mate of 
progression-free survival at 3 years is only 23%, even with 
subsequent high-dose chemotherapy and autologous 
stem-cell trans plantation.7 This situation empha sises the 
importance of ﬁ rst-line treatment when crucial issues are 
still unresolved, such as establishing the optimum 
rituximab dose and schedule as well as the opti mum 
chemotherapy regimen to combine with rituximab.
Two randomised studies done in the so-called pre-
rituximab era showed that the intensiﬁ ed doxorubicin, 
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cyclophosphamide, vindesine, bleomycin, and prednisone 
chemotherapy regimen (ACVBP) with subsequent 
sequential consolidation, compared with standard CHOP, 
can improve the outcome both in low-risk8 and high-risk9 
groups of patients, according to the International 
Prognostic Index for aggressive lymphoma.10 Similarly, the 
Deutsche Studiengruppe Hochmaligne Non-Hodgkin-
Lymphome11 showed that the addition of etoposide to 
CHOP improves the event-free survival of patients younger 
than 60 years with aggressive lymph oma. However, in a 
subsequent study assessing the outcomes of a subgroup of 
patients receiving CHOP plus etoposide in combination 
with rituximab compared with those receiving CHOP in 
combination with rituximab, the advantage conferred by 
CHOP plus etoposide disappeared, leading to the 
hypothesis that rituximab could have an equalising eﬀ ect 
on diﬀ erences exhibited by chemotherapy regimens.5
To prospectively assess the role of a dose-intensive 
regimen in combination with rituximab, GELA in 2003 
started a multicentre, phase 3, open-label, randomised trial 
(LNH03-2B), comparing the eﬃ  cacy and safety of ACVBP 
plus rituximab (R-ACVBP) versus standard CHOP plus 
rituximab (R-CHOP) in a selected population of patients 
aged 18–59 years with diﬀ use large B-cell lymphoma.
Methods
Participants
Between December, 2003, and December, 2008, in ac cor-
dance with our protocol, we did a phase 3 multicentre 
randomised trial in 73 haematology or oncology depart-
ments of GELA in France, Belgium, and Switzerland. 
Patients were eligible if they were aged 18–59 years and 
had untreated diﬀ use large B-cell lymphoma that had 
been diagnosed in accordance with the WHO classi-
ﬁ cation.12 We required that patients had only one adverse 
prognostic factor as deﬁ ned by the age-adjusted 
International Prognostic Index10 (raised lactate dehydro-
genase, Ann Arbor stage III or IV, or Eastern Cooperative 
Oncology Group [ECOG] performance status 2–413); a 
minimum life expectancy of 3 months; and negative HIV, 
hepatitis B virus, and hepatitis C virus serology tests 
(except after vaccination). Patients were not eligible if 
they had T-cell lymphoma; CNS or meningeal involvement 
by lymphoma; contraindication to any drug included in 
the chemotherapy regimens; any serious, active disease 
(according to the investigator’s decision); poor renal 
function (creatinine >150 mmol/L) or poor hepatic 
function (total bilirubin >30 mmol/L, trans aminases 
>2·5-times the maximum normal level), unless these 
abnormalities were related to the lymphoma; poor bone-
marrow reserve as deﬁ ned by a neutrophil concentration 
lower than 1·5×10⁹/L or a platelet concen tration lower 
than 100×10⁹/L, unless related to bone-marrow inﬁ l-
tration; any history of cancer during the past 5 years, with 
the exception of non-melanoma skin tumours or stage 0 
(in situ) cervical carcinoma; treatment with any 
investigational drug within 30 days before the planned 
ﬁ rst cycle of chemotherapy and during the study; or any 
history of treated or untreated indolent lymphoma.
We required patients to provide written informed consent 
before registration. Our study complied with all provisions 
of the Declaration of Helsinki and its amendments and 
was done in accordance with good clinical practice 
guidelines. Our protocol and informed consent forms were 
approved by the local and national institutional review 
boards in each participating centre and country.
Randomisation and masking
Our trial was not masked. We randomly assigned patients 
in a one-to-one ratio to receive R-ACVBP or R-CHOP. 
Investigators enrolled the participants, and assignment 
to treatment was done with a computer-assisted random-
isation allocation sequence with a block size of four 
generated by a statistician centrally at the Groupe d’Etude 
des Lymphomes de l’Adulte—Recherche Clinique 
(GELARC) oﬃ  ces with a fax process, without the 
intervention of the investigators. Treatment allocation 
was stratiﬁ ed by centre.
Procedures
The extent of the disease was assessed by physical 
examination; relevant laboratory tests; CT of the chest, 
abdomen, and pelvis (although MRI was not excluded, 
only CT was mandated by the protocol); cerebrospinal 
ﬂ uid examination; bone-marrow biopsy; and other 
investigational pro cedures, depending on clinical 
symptoms. The stage of lymphoma was deﬁ ned in 
accordance with the Ann Arbor classiﬁ cation. ¹⁸F-ﬂ uoro-
de oxy glucose (¹⁸F-FDG) PET was not mandated for 
staging or assessment of response to treatment. Tumour 
measurements were assessed by the treating physician or 
local radiologist. We deﬁ ned bulky disease as any mass 
10 cm or greater at the maximum diameter. Performance 
status was assessed in accordance with the ECOG scale,13 
and the lactate dehydrogonase level was expressed as the 
ratio of the maximum value to the normal value.
A central review was done by at least two pathologists 
from GELA, without knowledge of the patient outcome, 
to conﬁ rm the diagnosis of CD20-positive diﬀ use large 
B-cell lymphoma. Tumours were classiﬁ ed in accordance 
with the WHO classiﬁ cation.12 Members of the reference 
pathology panel are listed in the acknowledgments.
Figure 1 shows the protocol outline. Our R-ACVBP 
regimen consisted of an induction phase of four cycles of 
R-ACVBP with a subsequent consolidation phase 
containing diﬀ erent treatment sequences. A cycle of 
R-ACVBP comprised 375 mg/m² rituximab, 75 mg/m² 
doxorubicin, and 1200 mg/m² cyclophosphamide on 
day 1; 2 mg/m² vindesine and 10 mg bleomycin on days 1 
and 5; and 60 mg/m² prednisone on days 1–5. Each cycle 
of R-ACVBP was repeated every 2 weeks. Granulocyte 
colony-stimulating factor (ﬁ lgrastim) was also given 
subcutaneously from day 6 to 13. A sequential 
consolidation was given 4 weeks after completion of the 
For the LNH03-2B protocol see 
http://lnh03.gela.org/
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fourth cycle of R-ACVBP, consisting of two cycles of 
methotrexate (3 g/m²) and calcium folinate rescue, with 
four subsequent cycles of rituximab (375 mg/m²) 
combined with etoposide (300 mg/m²) and ifosfamide 
(1500 mg/m²), and ﬁ nally two cycles of cytarabine 
(100 mg/m²) given sub cutaneously for 4 days, with each 
consolidation course being given at 2-week intervals. The 
R-CHOP regimen consisted of eight cycles repeated at 
3-week intervals. Each cycle comprised 375 mg/m² 
rituximab, 50 mg/m² doxorubicin, 750 mg/m² cyclo-
phosphamide, and 1·4 mg/m² vincristine (up to a 
maximum dose of 2 mg) on day 1 and 60 mg/m² 
prednisone on days 1–5. During the ﬁ rst four cycles, the 
theoretical dose intensity of the R-ACVBP regimen, 
compared with R-CHOP, increased by a factor of 2·25 for 
doxorubicin (37·5 mg/m² per week vs 16·7 mg/m² per 
week), 2·4 for cyclophosphamide (600 mg/m² per week vs 
250 mg/m² per week), and 1·5 for rituximab (187·5 mg/m² 
per week vs 125 mg/m² per week). Patients received 15 mg 
of intrathecal methotrexate on day 1 of the ﬁ rst four cycles 
in both study groups for prophylaxis of the CNS. 
Radiotherapy was not permitted in our protocol.
Tumour responses were assessed by the local inves-
tigator after four cycles of R-ACVBP and R-CHOP and at 
the end of treatment in each group. Responses were 
classiﬁ ed as complete response, unconﬁ rmed complete 
response, or partial response. The disease state was 
identiﬁ ed as stable disease or progressive disease. 
Responses and disease states were based on the 
International Workshop 1999 criteria.14 Follow-up was 
undertaken by the local investigator. During the ﬁ rst 
2 years after treatment, assessment consisted of physical 
examination and laboratory tests every 3 months, and CT 
of the chest, abdomen, and pelvis every 6 months. 
Thereafter, physical examination and laboratory tests 
were done every 6 months and CT every year.
All adverse events reported by the patient or recorded 
by the investigator were collected from the case report 
form in predeﬁ ned categories. An adverse event was 
deﬁ ned as any adverse change from the patient’s baseline 
charac ter istics, independent of treatment status. Each 
event was graded according to the National Cancer 
Institute Common Toxicity Criteria grading system 
(version 3.0). All grade 3 and 4 events and grade 2 
infections were recorded in detail. Grade 1 and 2 adverse 
events were not extensively described.
Statistical analysis
We used event-free survival, our primary endpoint, to 
assess sample size. In our previous LNH-98-5 study,2 we 
estimated that treatment with R-CHOP conferred a 2-year 
event-free survival rate of 75% in the population of patients 
with one factor from the age-adjusted International 
Prognostic Index. To detect a change in the 2-year event-
free survival from 75% to 85% in the R-ACVBP group, we 
calculated that 380 patients randomly assigned at a ratio 
of one to one between the two treatment groups, recruited 
over 4 years, and followed up for a minimum of 1 year, 
would be needed to achieve 100 events and 80% power at 
the overall 5% (two-sided) signiﬁ cance level with a log-
rank test. We planned an interim analysis on the basis of 
40 events after 2 years of inclusion and a follow-up of a 
minimum of 1 year. We used the O’Brien–Fleming 
α-spending function to maintain the overall signiﬁ cance 
level, with α=0·0008 at interim analysis and 0·05 at ﬁ nal 
analysis. Because our threshold of signiﬁ cance was not 
met at this interim analysis, we completed the second 
stage of our trial.
We measured event-free survival from the date of 
randomisation to the date of the ﬁ rst event. We deﬁ ned 
events as death from any cause, disease progression 
during or after treatment, relapse for complete responders 
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Figure 1: Protocol outline
R-ACVBP=rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone. R-CHOP=rituximab, doxorubicin, cyclophosphamide, vincristine, 
and prednisone.
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and unconﬁ rmed complete responders, and implemen-
tation of any lymphoma treatment not stipulated by our 
protocol, including radiotherapy. Our secondary end-
points were response to treatment, progression-free 
survival, disease-free survival, overall survival, safety and 
the rate of CNS progression or relapse. We measured 
progression-free survival from the date of randomisation 
to the date of disease progression or relapse or death from 
any cause, disease-free survival from the time of 
attainment of a complete response or unconﬁ rmed 
complete response to disease recurrence or death caused 
by lymphoma or treatment-related toxic eﬀ ects, and 
overall survival from the date of randomisation to the date 
of death from any cause.
We computed event-free, progression-free, disease-
free, and overall survival curves by the Kaplan-Meier 
method and compared them by the log-rank test. We 
calculated hazard ratios (HR) and 95% CIs with a Cox 
proportional-hazards analysis. We did univariate 
analyses to assess the eﬀ ect of pretreatment-speciﬁ ed 
factors (age, sex, stage, number of extranodal sites, 
presence or absence of bone marrow involvement, 
presence or absence of bulky disease, B symptoms, 
lactate dehydro genase concentration, β2 microglobulin 
concentration, serum albumin concentration) on 
progression-free and overall survival. Interaction terms 
between these factors and treatment group assignments 
were also assessed with Cox analysis to detect 
heterogeneity of treatment eﬀ ect sizes according to the 
factor levels.
For each drug we calculated dose intensity as observed 
dose intensity divided by planned dose intensity. We 
expressed observed dose intensity as observed cumulative 
dose received during the ﬁ rst 4 cycles divided by observed 
duration between the ﬁ rst and fourth cycles. We deﬁ ned 
380 patients were randomly assigned to a treatment group
196 were assigned to
receive R-ACVBP
184 were assigned to
receive R–CHOP
1 withdrew consent before
treatment
196 received at least





161 completed treatment 164 completed treatment
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Figure 2: Trial proﬁ le
R-ACVBP=rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and 
prednisone. R-CHOP=rituximab, doxorubicin, cyclophosphamide, vincristine, 
and prednisone.
R-ACVBP group (n=196) R-CHOP group (n=183)
Sex
Male 116 (59%) 109 (60%)
Female 80 (41%) 74 (40%)
Median age, years (range, IQR) 47 (18·0–59·0, 36·0–54·5) 48 (19·0–59·0, 36·0–54·0)
ECOG performance status
0–1 195 (99%) 182 (99%)
2–4 1 (1%) 1 (1%)
B symptoms
No 137 (70%) 136 (74%)
Yes 59 (30%) 47 (26%)
Ann Arbor stage
I–II 81 (41%) 80 (44%)
III–IV 115 (59%) 93 (51%)
Largest mass diameter >10 cm
No 158 (81%) 137 (75%)
Yes 38 (19%) 45 (26%)
Lactate dehydrogenase concentration
Normal 119 (61%) 94 (51%)
Raised 77 (39%) 89 (49%)
Number of extranodal sites
0–1 148 (76%) 133 (73%)
>1 48 (24%) 50 (27%)
Bone-marrow involvement
No 165 (84%) 155 (85%) 
Yes 23 (12%) 27 (15%)
Not assessed 8 (4%) 1 (1%)
Age-adjusted International Prognostic Index*
0 5 (3%) 7 (4%)
1 189 (96%) 169 (92%)
2 2 (1%) 7 (4%)
Histology
Not reviewed 23 (12%) 12 (7%)
Reviewed 173 (88%) 171 (93%)
Diﬀ use large B-cell lymphoma 156 (90%) 161 (94%)
Not diﬀ use large B-cell lymphoma 13 (8%) 6 (4%)
Burkitt’s lymphoma 5 2
Follicular lymphoma 4 3
Mantle cell lymphoma 1 0
Marginal zone lymphoma 1 1
Hodgkin’s lymphoma 2 0
Unclassiﬁ ed B-cell lymphoma 4 (2%) 4 (2%)
Data are n (%) unless otherwise stated. R-ACVBP=rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and 
prednisone. R-CHOP=rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone. ECOG=Eastern Cooperative 
Oncology Group. *Some included patients had an age-adjusted International Prognostic Index other than 1 at data review.
Table 1: Baseline characteristics
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planned dose intensity as total planned cumulative dose 
received during the ﬁ rst 4 cycles divided by the theoretical 
time elapsed between the ﬁ rst and fourth cycles (56 days 
for R-ACVBP and 84 for R-CHOP).
Our analyses of eﬃ  cacy and safety were of the intention-
to-treat population. One patient who withdrew consent 
before any procedure was excluded from this population. 
All p values are two-sided. Statistical analyses were done 
with SAS 9.1.3 software by the investigators of the 
GELARC statistical oﬃ  ce. This study is registered with 
ClinicalTrials.gov, number NCT00140595.
Role of the funding source
GELA, via GELARC, was involved in the random assign-
ment procedure, distribution and collection of case report 
forms, data entry and validation, coordination of moni-
toring procedures, elaboration and mailing of queries, 
reporting of serious adverse events, coordination of histo-
logical review, relation with investigators, trans mission of 
enrolment status to the sponsor, statistical analy sis, and 
production of the report. Amgen had no role in study 
design, data collection, data analysis, data inter pretation, 
or writing of the report. The corres ponding author had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 2 shows the trial proﬁ le. We enrolled 380 patients 
into our trial, of which 379 received at least one dose of 
the protocol-planned treatment. The main characteristics 
of our patients were similar in the two groups (table 1). 
The main criteria providing an age-adjusted Inter-
national Prognostic Index score of 1 were raised lactate 
de hydrogenase concentration and Ann Arbor stage III–IV 
in 44% and 55% of patients, respectively. 21 patients had 
an age-adjusted International Prognostic Index score 
other than 1 (table 1). Central pathological review 
was completed for 344 patients (91%), with diﬀ use large 
B-cell lymphoma conﬁ rmed in 90% of the R-ACVBP 
group and 94% of the R-CHOP group. At the data-cutoﬀ  
point, Jan 1, 2010, the median follow-up was 44 months 
(IQR 27–53).
54 patients did not complete either treatment regimen 
(ﬁ gure 2). 190 patients (97%) in the R-ACVBP group 
received the ﬁ rst four cycles of the planned treatment 
and 177 (97%) in the R-CHOP group. The median 
interval between these cycles was 14 days (range 12–57, 
IQR 14–17) in the R-ACVBP group and 21 days (14–62, 
21–21) in the R-CHOP group. Based on data collected 
from the population who received the ﬁ rst four cycles of 
each treatment, the received dose intensities for 
doxorubicin were 92·1%, for cyclophosphamide were 
93·0%, and for rituximab were 92·3% of the planned 
dose for R-ACVBP, and 98·4%, 98·6%, and 98·6% for 
R-CHOP, respectively.
Fewer events were recorded in the R-ACVBP group 
than the R-CHOP group (table 2, ﬁ gure 3). Event-free 
survival was signiﬁ cantly longer for patients treated with 
R-ACVBP than for those treated with R-CHOP 
(p=0·0035), with 3-year estimates of 81% (95% CI 75–86) 
for R-ACVBP and 67% (59–73) for R-CHOP. The HR of 
the R-ACVBP group for event-free survival shows that 
this regimen reduced the risk of experiencing an event 
by 44% compared with R-CHOP in this population 
(ﬁ gure 3). Progression-free survival was signiﬁ cantly 
longer in the R-ACVBP group, resulting in a 3-year 
progression-free survival of 87% (81–91) with R-ACVBP 
and 73% (66–79) with R-CHOP (p=0·0015; ﬁ gure 3).
The overall response rate was 90% in the R-ACVBP 
group and 87% in the R-CHOP group (p=0·47; table 3). A 
complete response or unconﬁ rmed complete response 
was achieved in 162 patients (83%) in the R-ACVBP group 
and 146 (80%) in the R-CHOP group (p=0·46). In complete 
responders, the disease-free survival was signiﬁ cantly 
longer in the R-ACVBP group, with a 3-year estimate of 
91% (95% CI 85–95) compared with 80% (73–86) in the 
R-CHOP group (p=0·0019; ﬁ gure 3). 15 patients in the 
R-ACVBP group and 33 in the R-CHOP group experienced 
a relapse. There was no CNS relapse in the R-ACVBP 
group but two in the R-CHOP group. There were fewer 
deaths in the R-ACVBP group than the R-CHOP group 
(table 2). Overall survival diﬀ ered signiﬁ cantly, with a 
3-year estimate of 92% (87–95) in the R-ACVBP group and 
84% (77–89) in the R-CHOP group (p=0·0071; ﬁ gure 3).
Per-protocol analyses of patients who met all eligibility 
criteria, who had conﬁ rmed diﬀ use large B-cell lymphoma 
R-ACVBP group R-CHOP group
Events for event-free survival 40 (20%) 63 (34%)
Unplanned treatment for lymphoma 15 14
Unplanned chemotherapy 13 10
Unplanned radiotherapy 2 4
Progression or relapse 19 43
Death 6 6
Events for progression-free survival 28 (14%) 51 (28%)
Progression of relapse 21 44
Death 7 7
Events for overall survival 15 (8%) 31 (17%)
Lymphoma* 8 22
Unrelated to lymphoma progression during treatment 5 3
Unrelated to lymphoma progression after treatment
Second cancer ·· 2
Cardiac cause 1 ··
Pneumonitis ·· 2
Gastric haemorrhage ·· 1
Suicide ·· 1
Unknown 1 ··
Data are n (%) unless otherwise stated. R-ACVBP=rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, 
and prednisone. R-CHOP=rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone. *Deaths from 
lymphoma progression or related to treatment of relapse or progression.
Table 2: Analysis of endpoints in the intention-to-treat population
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at histology review, and who received at least four cycles 
of the allocated treatment (165 patients in the R-ACVBP 
group and 156 patients in the R-CHOP group) conﬁ rmed 
the results of our intention-to-treat analyses: event-free 
survival (p=0·0027), progression-free survival (p=0·0011), 
and overall survival (p=0·0023).
The presence of a bulky mass was the only factor 
identiﬁ ed as unfavourable for overall survival (HR 0·40, 
95% CI 0·22–0·72) but not for progression-free survival 
(0·72, 0·44–1·19). 3-year progression-free survival of 
patients with bulky disease was 77% (95% CI 58–88) in 
the R-ACVBP group and 73% (58–84) in the R-CHOP 
group (HR 0·69; p=0·40), and for patients without any 
mass larger than 10 cm diameter was 89% (83–93) in the 
R-ACVBP group and 73% (65–85) in the R-CHOP group 
(HR 0·43; p=0·0017). Interactions between any baseline 
factor and treatment group were not signiﬁ cant.
The most common adverse events were haematological 
toxic eﬀ ects in both groups (table 4). Patients receiving 
R-ACVBP had higher incidences of anaemia, thrombo-
cytopenia, neutropenia, and febrile neutropenia, which 
were also more commonly grade 3 or 4, than the R-CHOP 
group. Recorded infections during neutropenic periods 
were also more common in the R-ACVBP group. Grade 3 
or 4 mucositis was another adverse event associated with 
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Figure 3: Kaplan-Meier estimates of outcomes by treatment group
Event-free survival for the 379 patients in the intention-to-treat population (A). Progression-free survival for the 379 patients in the intention-to-treat population (B). Disease-free survival for the 
315 patients who achieved complete or unconﬁ rmed complete response to treatment (C); the number of patients in these estimates is diﬀ erent from the number of patients in complete or 
unconﬁ rmed complete remission at the end of treatment because disease-free survival is calculated from the initial recorded response. Overall survival for the 379 patients in the intention-to-treat 
population (D). R-ACVBP=rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone. R-CHOP=rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone. 
HR=hazard ratio.
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group. At least one red-blood-cell transfusion was done 
in 99 (51%) of 196 patients in the R-ACVBP group and 
13 (7%) of 183 in the R-CHOP group; platelet transfusions 
were also done in 25 (13%) of 196 and one (1%) of 183, 
respectively. Adverse events that were judged serious 
were more common in the R-ACVBP group (82 [42%] of 
196 patients) than in the R-CHOP group (28 [15%] of 
183). There were ﬁ ve deaths unrelated to lymphoma 
progression during the treatment period in the R-ACVBP 
group (three sepsis, one unknown cause, and one 
intrathecal vindesine injection) and three in the R-CHOP 
group (two sepsis and one unknown cause). At the time 
of our analysis, one malignancy had been recorded for 
the R-ACVBP group (lung cancer) and two for the 
R-CHOP group (biliary duct and lung cancer).
Discussion
After more than 3 years of follow-up, all our study 
endpoints were met, with signiﬁ cant improvements of 
event-free, progression-free, disease-free, and overall 
survival in patients treated with R-ACVBP.
The introduction of rituximab in association with 
CHOP chemotherapy has substantially improved the 
outcome of patients with diﬀ use large B-cell lymphoma. 
However, the results of the R-CHOP regimen, which has 
been widely thought the standard of care, remains 
suboptimum in the treatment of younger patients. In 
recent years, several phase 2 trials have shown promising 
results regarding the association of intensive chemo-
therapy and rituximab.16–19 Most of these regimens were 
proposed for patients with high-risk disease and 
contained an intensive chemotherapy schedule with 
stem-cell support.16–18 By contrast, dose-adjusted EPOCH 
(etoposide, prednisone, vincristine, cyclophosphamide, 
and doxorubicin) is an intensiﬁ ed regimen where 
pharma codynamic dosing is on the basis of neutrophil 
nadir.19 A phase 2 study of dose-adjusted EPOCH plus 
rituximab showed promising outcomes in low and 
intermediate International Prognostic Index groups with 
progression-free survival similar to that of R-ACVBP.
ACVBP has been used in Europe to treat patients with 
aggressive lymphoma for the past 30 years.20,21 The 
regimen consists of two diﬀ erent phases. The ﬁ rst part is 
an induction phase of four cycles with higher doxorubicin 
and cyclophosphamide doses, given at a shortened 
interval. During the second phase, patients receive a 
sequential consolidation treatment with drugs not used 
during induction. ACVBP improves results over CHOP 
in comparative trials assessing patients with localised 
diﬀ use large B-cell lymphoma8 and patients with more 
advanced disease.9 The association of rituximab with 
ACVBP in patients younger than 60 years with an age-
adjusted International Prognostic Index score of 1, as in 
our trial, seems to improve progression-free survival 
from 81% at 2 years22 to 90%.
The lower rate of disease progression during the 
treatment phase and fewer relapses in patients who 
reached a complete response accounted for the prolonged 
progression-free survival and overall survival in our 
R-ACVBP group. However, we do not know which phase 
of the R-ACVBP regimen improves the outcome. A trial 
is ongoing that aims to assess the quality of remission 
after R-ACVBP and R-CHOP by comparing ¹⁸F-FDG PET 
after two and four induction cycles.23 The role of 
consolidation is probably important. High-dose metho-
trexate plus calcium folinate rescue is associated with 
a low risk of CNS relapse in diﬀ use large B-cell lymph-
oma.24 Ifosfamide, etoposide, and cytarabine, contained 
in the consolidation, are the most common drugs used 
in salvage regimens after relapse subsequent to 
anthracycline-based treatment.7
Outcome data in our patients treated with standard 





Complete response 114 (58%) 96 (52%)
Unconﬁ rmed complete response 48 (24%) 50 (27%)
Partial response 14 (7%) 14 (8%)
Stable disease 4 (2%) 1 (1%)
Progressive disease 7 (4%) 17 (9%)
Death 5 (3%) 3 (2%)
Not assessed 4 (2%) 2 (1%)
Data are n (%). R-ACVBP=rituximab, doxorubicin, cyclophosphamide, vindesine, 
bleomycin, and prednisone. R-CHOP=rituximab, doxorubicin, cyclophosphamide, 
vincristine, and prednisone. Response to treatment was assessed in accordance 
with the International Workshop 1999 criteria.14
Table 3: Response to treatment by treatment group
Any grade Grade 3 or greater
R-ACVBP group R-CHOP group R-ACVBP group R-CHOP group
Anaemia 194 (99%) 138 (75%) 68 (35%) 10 (5%)
Neutropenia 189 (86%) 157 (83%) 153 (78%) 118 (64%)
Thrombocytopenia 151 (77%) 56 (31%) 59 (30%) 6 (3%)
Febrile neutropenia 77 (39%) 16 (9%) 75 (38%) 16 (9%)
Infection in neutropenic period 34 (17%) 12 (7%) 26 (13%) 7 (4%)
Infection out of neutropenic period 32 (16%) 19 (10%) 9 (5%) 5 (3%)
Mucositis 106 (54%) 25 (14%) 35 (18%) 0
Nausea or vomiting 69 (35%) 56 (31%) 6 (3%) 4 (2%)
Diarrhoea 31 (16%) 16 (9%) 1 (1%) 1 (1%)
Cardiac-related toxic eﬀ ects 5 (3%) 1 (1%) 0 1 (1%)
Aminotransferase elevation 58 (30%) 50 (27%) 4 (2%) 4 (2%)
Creatinine elevation 11 (6%) 8 (4%) 1 (1%) 0
Lung-related toxic eﬀ ects 33 (17%) 15 (8%) 2 (1%) 2 (1%)
Neurological toxic eﬀ ects 50 (30%) 46 (25%) 11 (6%) 4 (2%)
Vascular toxic eﬀ ects 21 (11%) 5 (3%) 13 (7%) 2 (1%)
Rash 51 (26%) 19 (10%) 3 (2%) 0
Other toxic eﬀ ects 130 (66%) 118 (64%) 25 (13%) 14 (8%)
Data are the number and proportion of patients with an event in at least one cycle. Toxic-eﬀ ect grades are based on the 
National Cancer Institute Common Terminology Criteria (version 3.0).15
Table 4: Toxic eﬀ ects by treatment group
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(panel),2 but the 3-year event-free survival 67% (59–73) 
seems to be in the lower range of the equivalent 
population of the MabThera International Trial:5 74% 
(66–84) for bulk disease or 76% (67–86) for no bulk 
disease. In the MabThera International Trial, various 
chemotherapy regimens plus rituximab did not produce 
major diﬀ erences in outcome. However, 40% of the 
patients treated with the rituximab combination received 
radiotherapy. Whether radiotherapy could aﬀ ect the 
outcome in this population treated with R-CHOP is being 
studied at present by the Deutsche Studiengruppe fur 
Hochmaligne Non-Hodgkin-Lymphome (registered with 
ClinicalTrials.gov, number NCT00278408).
The proﬁ le of toxic eﬀ ects for the R-ACVBP regimen is 
well characterised. The induction phase is associated with 
noticeable haematological toxic eﬀ ects, which is why the 
regimen is only used in patients younger than 60 years.9 
Most patients experience substantial neutropenia between 
day 9 and day 13 of each cycle, with a substantial 
proportion (39%) having a febrile episode despite the use 
of growth factor. However, our trial and previous ones 
involving the ACVBP regimen25 have shown that life-
threatening complications related to treatment are 
uncommon in a population of patients younger than 
60 years with good performance status. The care of many 
patients included in our trial has been managed in the 
oncology departments of community hospitals of the 
73 participating centres from the GELA network. Although 
ACVBP is an intensiﬁ ed regimen, the total dose of 
doxorubicin and cyclophosphamide given is less than the 
dose received during eight cycles of CHOP. This dose 
might account for the somewhat low incidence of 
secondary malignancies and cardiac-related toxic eﬀ ects 
recorded in a large cohort of 2837 ACVBP-treated patients 
that were followed up over a median of 74 months.26 We 
plan to do long-term follow-up of our patient cohort.
In the context of chemotherapy, interactions between 
the microenvironment and cancer cells, especially lymph-
oma cells, are complex.27 There is some evidence that 
antibody-dependent cellular cytotoxicity mediated by 
activation of natural-killer cells contributes to the clinical 
response to rituximab.28 Investigators have postulated 
that intensive chemotherapy could compromise the 
eﬃ  cacy of rituximab by impairing immune cellular 
mechanisms.5 However, the results of our study do not 
favour such a hypothesis.
Modiﬁ cations of immunochemotherapy regimens are 
still worthwhile and are being assessed at present. In our 
selected population, we did not identify any factor to 
suggest that a speciﬁ c patient category would beneﬁ t from 
treatment over the other. The favourable results obtained 
with R-ACVBP front-line regimen should be further 
assessed in view of the biological heterogeneity of diﬀ use 
large B-cell lymphoma,29 to assess whether some patients 
with speciﬁ c subtypes are more to likely to beneﬁ t from 
this intensive therapy, as it has been suggested for dose-
adjusted EPOCH plus rituximab,19 whereas R-CHOP 
might be suﬃ  cient for others. The possibility of decreasing 
the intensity of immunochemotherapy could also be 
explored in selected patients who show a rapid response to 
treatment, assessed with interim PET. Pending these 
results and the advent of new targeted therapies in front-
line treatment, intensiﬁ ed immunochemotherapy with 
R-ACVBP represents an alternative to R-CHOP to improve 
survival in patients younger than 60 years with diﬀ use 
large B-cell lymphoma of low-intermediate risk.
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Interpretation
These studies have established the addition of the anti-CD20 monoclonal antibody 
rituximab with a chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) as a new standard of care. However, CHOP plus rituximab is suboptimum 
for a substantial number of patients who could relapse and are not salvaged by subsequent 
therapies. Our results show that rituximab combined to the intensiﬁ ed multidrug regimen of 
doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP), as ﬁ rst-line 
treatment, improves the survival of young patients with low-intermediate-risk diﬀ use large 
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